WAIVER UNDER LICENSE AGREEMENTLicense Agreement • October 13th, 2023 • Aileron Therapeutics Inc • Pharmaceutical preparations
THIS WAIVER UNDER LICENSE AGREEMENT (this “Waiver”) is made as of the date first written above (the “Effective Date”) by and among President and Fellows of Harvard College (“Harvard”), Dana-Farber Cancer Institute, Inc. (“DFCI”, and together with Harvard, the “Licensors”) and Aileron Therapeutics, Inc. (“Licensee”) with respect to that certain Amended and Restated License Agreement dated as of February 19, 2010 (the “License Agreement”). Capitalized terms not defined in this Waiver shall have the meanings given to them in the License Agreement.
